Bay Area and Taipei biotech AltruBio has raised $225 million in a Series B to move forward its experimental drug for ulcerative colitis and other chronic autoimmune conditions, it said Tuesday.
The round is the latest in a surge of funding for startups that seek to treat immune and inflammatory conditions, including $400 million for Mirador Therapeutics in March and $105 million for Attovia Therapeutics earlier this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.